查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
药物发现服务市场：2019-2029 年全球市场规模、份额、趋势分析、机会和预测报告
市场调查报告书
商品编码
1301796

药物发现服务市场：2019-2029 年全球市场规模、份额、趋势分析、机会和预测报告

Drug Discovery Services Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Process ; By Drug Type ; By Therapeutic Area ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2029 年，全球药物发现服务市场将增长 2.8 倍，达到 530 亿美元

由于製药和生物技术公司研发投资的增加、药物发现复杂性的增加、慢性病患病率的增加以及政府努力简化和加快药物开发和审批流程，全球药物发现服务市场正在蓬勃发展。

领先的战略咨询和市场研究公司 BlueWeave Consulting 最近估计，2022 年全球药物发现服务市场价值将达到 185 亿美元。 BlueWeave预测，在2023-2029年的预测期内，全球药物发现服务市场规模将以15.2%的年复合成长率增长，到2029年达到528亿美元。疾病日益复杂以及对个性化医疗的需求使得新药发现变得更具挑战性。这种复杂性需要多学科方法和专业知识，这可以通过外包获得。製药和生物技术公司大力投资研发活动，以发现新药和治疗方法。外包药物发现过程的某些阶段可以更有效地利用专业知识和资源。此外，製药公司、学术机构和 CRO 之间的合作伙伴关係在药物发现领域变得越来越普遍。这种伙伴关係促进知识共享、专业知识的获取和资源共享，从而促进创新并推动市场增长。

该报告的详细分析提供了有关全球药物发现服务市场的增长潜力、未来趋势和统计数据的信息。它还重点关注推动市场总规模预测的因素。该报告提供了全球药物发现服务市场的最新技术发展以及行业见解，以帮助决策者做出明智的战略决策。它还分析了市场的增长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球药物发现服务市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长动力
      • 慢性病患病率
      • 药物发现活动外包
      • 研发费用增加
    • 抑制因素
      • 严格的监管要求
      • 故障率高
    • 机会
      • 个性化医疗的出现
      • 越来越关注孤儿疾病和孤儿药物
    • 任务
      • 道德问题和公众认知
  • 技术进步/最新发展
  • 监管框架
  • 波特五力分析
  • 全球药物发现服务市场概况
  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
      • 化学服务
      • 生物服务
    • 按流程
      • 目标验证
      • 目标选择
      • H2L的识别
      • 候选人验证
      • 潜在客户优化
    • 按药物类型
      • 生物製剂
      • 小分子药物
    • 按治疗领域
      • 神经病学
      • 传染病和免疫系统疾病
      • 消化系统疾病
      • 瘤
      • 其他的
    • 按最终用户
      • 製药和生物技术公司
      • 学术机构
      • 其他的
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第4章北美药物发现服务市场

    • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按流程
    • 按药物类型
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
      • 我们
      • 按类型
      • 按流程
      • 按药物类型
      • 按治疗领域
      • 按最终用户
      • 加拿大
      • 按类型
      • 按流程
      • 按药物类型
      • 按治疗领域
      • 按最终用户

第5章欧洲药物发现服务市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按流程
    • 按药物类型
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第6章亚太药物发现服务市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按流程
    • 按药物类型
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第7章拉丁美洲药物发现服务市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按流程
    • 按药物类型
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第8章中东和非洲药物发现服务市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按类型
    • 按流程
    • 按药物类型
    • 按治疗领域
    • 按最终用户
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第9章竞争格局

  • 主要公司及其产品列表
  • 2022年全球药物发现服务企业市场份额分析
  • 通过运行参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作）

第10章COVID-19 对全球药物发现服务市场的影响

第11章公司简介（公司简介、财务矩阵、竞争格局、关键人才、主要竞争、联繫地址、战略展望、SWOT分析）

  • General Electric
  • Eurofins Scientific
  • Syngene International Limited
  • Wuxi AppTec
  • Frontage Labs
  • Domainex
  • WIL Research Laboratories LLC
  • Shanghai Medicilon, Inc.
  • Labcorp Drug Development
  • Jubilant Biosys Ltd.
  • Evotec
  • Shanghai ChemPartner
  • Charles River Laboratories
  • Merck & Co. Inc.
  • Thermo Fisher Scientific Inc.
  • Other Prominent Players

第12章主要战略建议

第13章调查方法

简介目录
Product Code: BWC23487

Global Drug Discovery Services Market Zooming 2.8X to Reach USD 53 Billion by 2029

Global drug discovery services market is booming due to the increasing R&D investments by pharmaceutical companies and biotechnology firms, complexity of drug discovery, increasing prevalence of chronic diseases, and government initiatives to streamline and expedite the drug development and approval process.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global drug discovery services market size at USD 18.5 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global drug discovery services market size to grow at a CAGR of 15.2% reaching a value of USD 52.8 billion by 2029. The discovery of new drugs has become more challenging due to the complexity of diseases and the need for personalized medicine. This complexity requires a multidisciplinary approach and specialized expertise, which can be obtained through outsourcing. Pharmaceutical companies and biotechnology firms are investing heavily in research and development activities to discover new drugs and therapies. Outsourcing certain stages of the drug discovery process allows them to access specialized expertise and resources more efficiently. Furthermore, collaborative partnerships between pharmaceutical companies, academic institutions, and CROs have become increasingly common in drug discovery. These partnerships facilitate knowledge sharing, access to specialized expertise, and resource pooling, fostering innovation and driving market growth.

Opportunity: Increasing Focus on Drug Research and Development

The pursuit of innovative and effective therapeutics is driving the pharmaceutical industry to allocate larger budgets towards R&D. As the global burden of diseases continues to rise, there is a growing demand for novel drugs that can address unmet medical needs. Pharmaceutical companies are motivated to invest more in R&D to discover breakthrough treatments, resulting in increased demand for drug discovery services. The advances in scientific knowledge and technologies have expanded the scope and complexity of drug discovery research. With the advent of genomics, proteomics, high-throughput screening, computational modelling, and other cutting-edge tools, the process of identifying and developing new drug candidates has become more intricate. These advancements require substantial investments in specialized equipment, expertise, and infrastructure, which in turn drive up R&D expenditures.

Impact of COVID-19 on the Drug Discovery Services Market

The COVID-19 pandemic had a profound impact on the drug discovery services market, affecting various aspects of the industry. The pandemic led to a heightened focus on infectious diseases. The urgent need for treatments and vaccines for COVID-19 drove significant investments and collaborations in research and development related to infectious diseases. Many drug discovery service providers redirected their efforts towards developing drugs and therapies specifically targeting the virus. This shift resulted in an increased demand for services related to target identification, lead optimization, and preclinical testing for infectious diseases. The limitations imposed by the pandemic accelerated the adoption of virtual screening and computational approaches in drug discovery. With physical laboratory work being restricted, drug discovery service providers increasingly relied on computer simulations, artificial intelligence, and machine learning algorithms to identify potential drug candidates. These technologies have played a crucial role in continuing research activities despite the limitations imposed by the pandemic. They enabled virtual collaborations, data analysis, and the identification of drug targets.

Global Drug Discovery Services Market - By Type:

Based on type, the global drug discovery services market is bifurcated into chemistry services and biology services segments. During the period in analysis, the chemistry services segment is expected to hold a significant market share due to the broad use of chemical services at various early stages of drug development to produce reliable drug candidates. The widespread use of chemistry in academia, biotechnology firms, and sizable pharmaceutical businesses also contributes to industry expansion.

Global Drug Discovery Services Market - By Process:

Based on process, the global drug discovery services market is segmented into target validation, target selection, hit-to-lead identification, candidate validation, and lead optimization. During the forecast period, Hit-To-Lead Identification is expected to hold a significant market share. Hit-To-Lead Identification is an early stage in the drug discovery process, where potential drug candidates, known as hits, are identified and further optimized into leads. As drug discovery efforts increase, there is a growing demand for services that focus on this crucial stage. The combination of specialized expertise, advanced screening technologies, computational approaches, and the ability to optimize hits into leads positions the Hit-To-Lead Identification segment as a significant player in the global drug discovery services market.

Competitive Landscape:

The drug discovery services market is fragmented, with numerous players serving the market. The key players dominating the global drug discovery services market include General Electric, Eurofins Scientific, Syngene International Limited, Wuxi AppTec, Frontage Labs, Domainex, WIL Research Laboratories LLC, Shanghai Medicilon, Inc., Labcorp Drug Development, Jubilant Biosys Ltd, Evotec, Shanghai ChemPartner, Charles River Laboratories, Merck & Co. Inc., Thermo Fisher Scientific Inc. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Drug Discovery Services Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Drug Discovery Services Market along with industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Drug Discovery Services Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Growing prevalence of chronic diseases
      • 3.2.1.2. Outsourcing of drug discovery activities
      • 3.2.1.3. Increasing R&D expenditure
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent regulatory requirements
      • 3.2.2.2. High failure rates
    • 3.2.3. Opportunities
      • 3.2.3.1. Emergence of personalized medicine
      • 3.2.3.2. Increasing focus on rare diseases and orphan drugs
    • 3.2.4. Challenges
      • 3.2.4.1. Ethical concerns and public perception
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry
  • 3.6. Global Drug Discovery Services Market Overview
  • 3.7. Market Size & Forecast, 2019-2029
    • 3.7.1. By Value (USD Billion)
  • 3.8. Market Share & Forecast
    • 3.8.1. By Type
      • 3.8.1.1. Chemistry Services
      • 3.8.1.2. Biology Services
    • 3.8.2. By Process
      • 3.8.2.1. Target Validation
      • 3.8.2.2. Target Selection
      • 3.8.2.3. Hit-To-Lead Identification
      • 3.8.2.4. Candidate Validation
      • 3.8.2.5. Lead Optimization
    • 3.8.3. By Drug Type
      • 3.8.3.1. Biologics
      • 3.8.3.2. Small Molecule Drugs
    • 3.8.4. By Therapeutic Area
      • 3.8.4.1. Neurology
      • 3.8.4.2. Infectious & Immune System Diseases
      • 3.8.4.3. Digestive System Diseases
      • 3.8.4.4. Oncology
      • 3.8.4.5. Others
    • 3.8.5. By End User
      • 3.8.5.1. Pharmaceutical & Biotechnology Companies
      • 3.8.5.2. Academic Institutes
      • 3.8.5.3. Others
    • 3.8.6. By Region
      • 3.8.6.1. North America
      • 3.8.6.2. Europe
      • 3.8.6.3. Asia Pacific (APAC)
      • 3.8.6.4. Latin America (LATAM)
      • 3.8.6.5. Middle East and Africa (MEA)

4. North America Drug Discovery Services Market

    • 4.1.1. Market Size & Forecast, 2019-2029
    • 4.1.2. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Type
    • 4.2.2. By Process
    • 4.2.3. By Drug Type
    • 4.2.4. By Therapeutic Area
    • 4.2.5. By End User
    • 4.2.6. By Country
      • 4.2.6.1. United States
      • 4.2.6.1.1. By Type
      • 4.2.6.1.2. By Process
      • 4.2.6.1.3. By Drug Type
      • 4.2.6.1.4. By Therapeutic Area
      • 4.2.6.1.5. By End User
      • 4.2.6.2. Canada
      • 4.2.6.2.1. By Type
      • 4.2.6.2.2. By Process
      • 4.2.6.2.3. By Drug Type
      • 4.2.6.2.4. By Therapeutic Area
      • 4.2.6.2.5. By End User

5. Europe Drug Discovery Services Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Process
    • 5.2.3. By Drug Type
    • 5.2.4. By Therapeutic Area
    • 5.2.5. By End User
    • 5.2.6. By Country
      • 5.2.6.1. Germany
      • 5.2.6.1.1. By Type
      • 5.2.6.1.2. By Process
      • 5.2.6.1.3. By Drug Type
      • 5.2.6.1.4. By Therapeutic Area
      • 5.2.6.1.5. By End User
      • 5.2.6.2. United Kingdom
      • 5.2.6.2.1. By Type
      • 5.2.6.2.2. By Process
      • 5.2.6.2.3. By Drug Type
      • 5.2.6.2.4. By Therapeutic Area
      • 5.2.6.2.5. By End User
      • 5.2.6.3. Italy
      • 5.2.6.3.1. By Type
      • 5.2.6.3.2. By Process
      • 5.2.6.3.3. By Drug Type
      • 5.2.6.3.4. By Therapeutic Area
      • 5.2.6.3.5. By End User
      • 5.2.6.4. France
      • 5.2.6.4.1. By Type
      • 5.2.6.4.2. By Process
      • 5.2.6.4.3. By Drug Type
      • 5.2.6.4.4. By Therapeutic Area
      • 5.2.6.4.5. By End User
      • 5.2.6.5. Spain
      • 5.2.6.5.1. By Type
      • 5.2.6.5.2. By Process
      • 5.2.6.5.3. By Drug Type
      • 5.2.6.5.4. By Therapeutic Area
      • 5.2.6.5.5. By End User
      • 5.2.6.6. Belgium
      • 5.2.6.6.1. By Type
      • 5.2.6.6.2. By Process
      • 5.2.6.6.3. By Drug Type
      • 5.2.6.6.4. By Therapeutic Area
      • 5.2.6.6.5. By End User
      • 5.2.6.7. Russia
      • 5.2.6.7.1. By Type
      • 5.2.6.7.2. By Process
      • 5.2.6.7.3. By Drug Type
      • 5.2.6.7.4. By Therapeutic Area
      • 5.2.6.7.5. By End User
      • 5.2.6.8. The Netherlands
      • 5.2.6.8.1. By Type
      • 5.2.6.8.2. By Process
      • 5.2.6.8.3. By Drug Type
      • 5.2.6.8.4. By Therapeutic Area
      • 5.2.6.8.5. By End User
      • 5.2.6.9. Rest of Europe
      • 5.2.6.9.1. By Type
      • 5.2.6.9.2. By Process
      • 5.2.6.9.3. By Drug Type
      • 5.2.6.9.4. By Therapeutic Area
      • 5.2.6.9.5. By End User

6. Asia-Pacific Drug Discovery Services Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Process
    • 6.2.3. By Drug Type
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By End User
    • 6.2.6. By Country
      • 6.2.6.1. China
      • 6.2.6.1.1. By Type
      • 6.2.6.1.2. By Process
      • 6.2.6.1.3. By Drug Type
      • 6.2.6.1.4. By Therapeutic Area
      • 6.2.6.1.5. By End User
      • 6.2.6.2. India
      • 6.2.6.2.1. By Type
      • 6.2.6.2.2. By Process
      • 6.2.6.2.3. By Drug Type
      • 6.2.6.2.4. By Therapeutic Area
      • 6.2.6.2.5. By End User
      • 6.2.6.3. Japan
      • 6.2.6.3.1. By Type
      • 6.2.6.3.2. By Process
      • 6.2.6.3.3. By Drug Type
      • 6.2.6.3.4. By Therapeutic Area
      • 6.2.6.3.5. By End User
      • 6.2.6.4. South Korea
      • 6.2.6.4.1. By Type
      • 6.2.6.4.2. By Process
      • 6.2.6.4.3. By Drug Type
      • 6.2.6.4.4. By Therapeutic Area
      • 6.2.6.4.5. By End User
      • 6.2.6.5. Australia & New Zealand
      • 6.2.6.5.1. By Type
      • 6.2.6.5.2. By Process
      • 6.2.6.5.3. By Drug Type
      • 6.2.6.5.4. By Therapeutic Area
      • 6.2.6.5.5. By End User
      • 6.2.6.6. Indonesia
      • 6.2.6.6.1. By Type
      • 6.2.6.6.2. By Process
      • 6.2.6.6.3. By Drug Type
      • 6.2.6.6.4. By Therapeutic Area
      • 6.2.6.6.5. By End User
      • 6.2.6.7. Malaysia
      • 6.2.6.7.1. By Type
      • 6.2.6.7.2. By Process
      • 6.2.6.7.3. By Drug Type
      • 6.2.6.7.4. By Therapeutic Area
      • 6.2.6.7.5. By End User
      • 6.2.6.8. Singapore
      • 6.2.6.8.1. By Type
      • 6.2.6.8.2. By Process
      • 6.2.6.8.3. By Drug Type
      • 6.2.6.8.4. By Therapeutic Area
      • 6.2.6.8.5. By End User
      • 6.2.6.9. Vietnam
      • 6.2.6.9.1. By Type
      • 6.2.6.9.2. By Process
      • 6.2.6.9.3. By Drug Type
      • 6.2.6.9.4. By Therapeutic Area
      • 6.2.6.9.5. By End User
      • 6.2.6.10. Rest of APAC
      • 6.2.6.10.1. By Type
      • 6.2.6.10.2. By Process
      • 6.2.6.10.3. By Drug Type
      • 6.2.6.10.4. By Therapeutic Area
      • 6.2.6.10.5. By End User

7. Latin America Drug Discovery Services Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Process
    • 7.2.3. By Drug Type
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By End User
    • 7.2.6. By Country
      • 7.2.6.1. Brazil
      • 7.2.6.1.1. By Type
      • 7.2.6.1.2. By Process
      • 7.2.6.1.3. By Drug Type
      • 7.2.6.1.4. By Therapeutic Area
      • 7.2.6.1.5. By End User
      • 7.2.6.2. Mexico
      • 7.2.6.2.1. By Type
      • 7.2.6.2.2. By Process
      • 7.2.6.2.3. By Drug Type
      • 7.2.6.2.4. By Therapeutic Area
      • 7.2.6.2.5. By End User
      • 7.2.6.3. Argentina
      • 7.2.6.3.1. By Type
      • 7.2.6.3.2. By Process
      • 7.2.6.3.3. By Drug Type
      • 7.2.6.3.4. By Therapeutic Area
      • 7.2.6.3.5. By End User
      • 7.2.6.4. Peru
      • 7.2.6.4.1. By Type
      • 7.2.6.4.2. By Process
      • 7.2.6.4.3. By Drug Type
      • 7.2.6.4.4. By Therapeutic Area
      • 7.2.6.4.5. By End User
      • 7.2.6.5. Rest of Latin America
      • 7.2.6.5.1. By Type
      • 7.2.6.5.2. By Process
      • 7.2.6.5.3. By Drug Type
      • 7.2.6.5.4. By Therapeutic Area
      • 7.2.6.5.5. By End User

8. Middle East & Africa Drug Discovery Services Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Process
    • 8.2.3. By Drug Type
    • 8.2.4. By Therapeutic Area
    • 8.2.5. By End User
    • 8.2.6. By Country
      • 8.2.6.1. Saudi Arabia
      • 8.2.6.1.1. By Type
      • 8.2.6.1.2. By Process
      • 8.2.6.1.3. By Drug Type
      • 8.2.6.1.4. By Therapeutic Area
      • 8.2.6.1.5. By End User
      • 8.2.6.2. UAE
      • 8.2.6.2.1. By Type
      • 8.2.6.2.2. By Process
      • 8.2.6.2.3. By Drug Type
      • 8.2.6.2.4. By Therapeutic Area
      • 8.2.6.2.5. By End User
      • 8.2.6.3. Qatar
      • 8.2.6.3.1. By Type
      • 8.2.6.3.2. By Process
      • 8.2.6.3.3. By Drug Type
      • 8.2.6.3.4. By Therapeutic Area
      • 8.2.6.3.5. By End User
      • 8.2.6.4. Kuwait
      • 8.2.6.4.1. By Type
      • 8.2.6.4.2. By Process
      • 8.2.6.4.3. By Drug Type
      • 8.2.6.4.4. By Therapeutic Area
      • 8.2.6.4.5. By End User
      • 8.2.6.5. South Africa
      • 8.2.6.5.1. By Type
      • 8.2.6.5.2. By Process
      • 8.2.6.5.3. By Drug Type
      • 8.2.6.5.4. By Therapeutic Area
      • 8.2.6.5.5. By End User
      • 8.2.6.6. Nigeria
      • 8.2.6.6.1. By Type
      • 8.2.6.6.2. By Process
      • 8.2.6.6.3. By Drug Type
      • 8.2.6.6.4. By Therapeutic Area
      • 8.2.6.6.5. By End User
      • 8.2.6.7. Algeria
      • 8.2.6.7.1. By Type
      • 8.2.6.7.2. By Process
      • 8.2.6.7.3. By Drug Type
      • 8.2.6.7.4. By Therapeutic Area
      • 8.2.6.7.5. By End User
      • 8.2.6.8. Rest of MEA
      • 8.2.6.8.1. By Type
      • 8.2.6.8.2. By Process
      • 8.2.6.8.3. By Drug Type
      • 8.2.6.8.4. By Therapeutic Area
      • 8.2.6.8.5. By End User

9. Competitive Landscape

  • 9.1. List of Key Players and Their Offerings
  • 9.2. Global Drug Discovery Services Company Market Share Analysis, 2022
  • 9.3. Competitive Benchmarking, By Operating Parameters
  • 9.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

10. Impact of Covid-19 on Global Drug Discovery Services Market

11. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 11.1. General Electric
  • 11.2. Eurofins Scientific
  • 11.3. Syngene International Limited
  • 11.4. Wuxi AppTec
  • 11.5. Frontage Labs
  • 11.6. Domainex
  • 11.7. WIL Research Laboratories LLC
  • 11.8. Shanghai Medicilon, Inc.
  • 11.9. Labcorp Drug Development
  • 11.10. Jubilant Biosys Ltd.
  • 11.11. Evotec
  • 11.12. Shanghai ChemPartner
  • 11.13. Charles River Laboratories
  • 11.14. Merck & Co. Inc.
  • 11.15. Thermo Fisher Scientific Inc.
  • 11.16. Other Prominent Players

12. Key Strategic Recommendations

13. Research Methodology

  • 13.1. Qualitative Research
    • 13.1.1. Primary & Secondary Research
  • 13.2. Quantitative Research
  • 13.3. Market Breakdown & Data Triangulation
    • 13.3.1. Secondary Research
    • 13.3.2. Primary Research
  • 13.4. Breakdown of Primary Research Respondents, By Region
  • 13.5. Assumptions & Limitations